Anticoagulation for patients with cancer and central venous catheters (Q24235260)

5

0 references

Francesca Sperati

6

0 references

Elie A Akl

1

0 references

Deborah J. Cook

7

Deborah Cook

0 references

Victor E D Yosuico

4

Victor E D Yosuico

0 references

Srinivasa Rao Vasireddi

2

Srinivasa Rao Vasireddi

0 references

Sameer Gunukula

3

Cochrane Database of Systematic Reviews

Sameer Gunukula

0 references

publication date

13 April 2011

0 references

published in

0 references

cites work

Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies--a randomized, controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Prophylactic urokinase in the management of long-term venous access devices in children: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Thromboembolic complications related to indwelling central venous catheters in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Catheter-associated thrombosis: thromboprophylaxis or not?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Lack of efficacy of twice-weekly urokinase in the prevention of complications associated with Hickman catheters: a multicentre randomised comparison of urokinase versus heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Randomized trial of prevention of catheter-related bloodstream infection by continuous infusion of low-dose unfractionated heparin in patients with hematologic and oncologic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Malignancies, prothrombotic mutations, and the risk of venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Thrombotic complications of central venous catheters in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

The thrombophilic state induced by therapeutic agents in the cancer patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Randomized trials stopped early for benefit: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Benefit of heparin in central venous and pulmonary artery catheters: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Can low-molecular-weight heparins improve outcome in patients with cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Venous Thromboembolism Associated With Long-Term Use of Central Venous Catheters in Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Prognosis of Cancers Associated with Venous Thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

Ultrasound screening for internal jugular vein thrombosis aids the detection of central venous catheter-related infections in patients with haemato-oncological diseases: a prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

7 January 2021

Central venous catheter related thrombosis in haematology patients and prediction of risk by screening with Doppler‐ultrasound

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

7 January 2021

Thrombosis, markers of thrombotic risk, indwelling central venous catheters and antithrombotic prophylaxis using low-dose warfarin in subjects with malignant disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

7 January 2021

Is antithrombotic prophylaxis required in cancer patients with central venous catheters? Yes for special patient groups

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

7 January 2021

Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

7 January 2021

Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solution: A randomized, multicenter, double-blind trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

7 January 2021

Thrombosis: the major Hickman catheter complication in patients with solid tumor

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

7 January 2021

Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006468.PUB4

7 January 2021